Mirabegron is a medicine for an overactive bladder, which causes sudden strong urges to pee and leaks. It is taken as a pill once a day, and there is also a liquid form for children. It works by relaxing the bladder muscle so the bladder can hold more urine.
Every report comes from a Lived member, sent anonymously.
Have you tried Myrbetriq (Mirabegron) for Overactive Bladder?
Mirabegron, sold as Myrbetriq and as a generic, is a prescription medicine for overactive bladder in adults. Overactive bladder causes sudden, hard-to-delay urges to urinate, frequent trips to the toilet and, for some people, leaking before reaching one (urge incontinence). Mirabegron can be used on its own or together with solifenacin (Vesicare), an older type of bladder medicine, when one drug alone is not enough. Mirabegron is also approved for children 3 years and older with neurogenic detrusor overactivity, a bladder that contracts unpredictably because of a problem with the brain, spinal cord or nerves. Younger or lighter children take Myrbetriq Granules, a liquid made up from granules, while children who weigh at least 35 kg (about 77 pounds) can take either the liquid or the tablets. Mirabegron belongs to a group called beta-3 agonists; vibegron (Gemtesa) is the other one available in the US. The main alternative group is antimuscarinic medicines, such as oxybutynin and solifenacin. US urology guidelines consider the two groups about equally effective, so the choice often comes down to side effects and other health conditions. Bladder training and other habits, such as timed trips to the toilet, managing fluids and cutting back on caffeine and alcohol, are recommended for everyone with overactive bladder, with or without medicine.
The bladder wall is a muscle that should stay relaxed while the bladder fills and contract only when you choose to urinate. In overactive bladder, it tightens too early, which creates urgency before the bladder is full. Mirabegron activates beta-3 receptors on this muscle, signaling it to relax during the filling phase. The bladder can then hold more urine before urges start, which can mean fewer trips to the toilet and fewer leaks. This approach differs from antimuscarinic medicines, which block a different nerve signal that triggers bladder contractions. Because it works differently, mirabegron appears less likely to cause the dry mouth and constipation those medicines are known for, and the two types can be combined when one is not enough.
For adults, mirabegron is an extended-release tablet taken once a day, usually starting at 25 mg. If symptoms have not improved enough after 4 to 8 weeks, the prescriber may raise the dose to 50 mg, which is the maximum. When it is combined with solifenacin, both are taken once daily. Adults can take the tablet with or without food. The tablet is designed to release the medicine slowly over the day, so it must be swallowed whole with water and not chewed, split or crushed. People with significant kidney or moderate liver problems usually stay at 25 mg, and mirabegron is not recommended for people with kidney failure (including those on dialysis) or severe liver disease. For children, the dose is based on weight, and both the liquid and the tablets are taken with food. The tablets and Myrbetriq Granules are different products and are not interchangeable milligram for milligram, so they should never be swapped or mixed to make up a dose. The liquid should be measured with the device provided and taken within an hour of being prepared. If a dose is missed, take it when you remember unless more than 12 hours have passed; in that case, skip it and take the next dose at the usual time.
In adult trials, the most common side effects were higher blood pressure, cold-like symptoms such as a sore throat or stuffy nose, urinary tract infections and headache. Dizziness, nausea, constipation and diarrhea can also occur. When mirabegron is combined with solifenacin, dry mouth, constipation, urinary tract infections and a faster heartbeat become more common, mostly because of the solifenacin. In children, urinary tract infections, cold-like symptoms, constipation and headache were most common. An irregular heartbeat (atrial fibrillation) has been reported in a small number of people. A racing, fluttering or irregular heartbeat is worth reporting to the prescriber. Rarely, mirabegron causes angioedema, a deep swelling of the face, lips, tongue or throat. It can appear after the first dose or only after several doses. Swelling of the tongue or throat, or any trouble breathing or swallowing, can block the airway: stop the medicine and get emergency care right away.
Mirabegron can raise blood pressure, usually by a small amount, though the rise can be larger in children under 12. Blood pressure is written as two numbers: the top (systolic) number is the pressure while the heart beats, and the bottom (diastolic) number is the pressure between beats. Mirabegron is not recommended for adults whose blood pressure is severely high and uncontrolled, meaning a top number of 180 or higher or a bottom number of 110 or higher. People with high blood pressure should have it checked regularly after starting, and should tell the prescriber if their readings at home climb. Mirabegron can occasionally make it hard to empty the bladder fully. This risk mainly applies to people whose urine flow is already blocked, for example by an enlarged prostate, and to people also taking an antimuscarinic bladder medicine such as solifenacin. A weak stream, straining or a feeling that the bladder has not emptied should be reported to the prescriber promptly. Mirabegron slows a liver enzyme called CYP2D6, which breaks down a number of other medicines, so their levels in the blood can rise. This matters most for drugs whose safe dose range is narrow, and includes some heart and psychiatric medicines, such as the beta blocker metoprolol and the tricyclic antidepressant desipramine. It also raises levels of digoxin, a heart rhythm and heart failure medicine; people starting both usually begin on the lowest digoxin dose and have blood levels checked. Give the prescriber and pharmacist a full list of medicines and supplements. There are no studies of mirabegron in pregnancy, and it is not known whether it passes into breast milk. Anyone who is pregnant, planning a pregnancy or breastfeeding should discuss whether to use it.
Some people notice fewer urges or trips to the toilet within the first few weeks, but the full benefit may take 8 weeks or longer. Prescribers usually review progress after 4 to 8 weeks to decide whether to raise the dose, add another treatment or switch. Keeping a simple bladder diary of trips, leaks and urgency before and during treatment makes it easier to judge whether it is helping. The improvement is real but usually partial rather than complete. In the main 12-week trials, adults started out urinating about 11 to 12 times a day with 2 to 3 leaks. On mirabegron, both fell, but people taking a placebo also improved, and the added effect of the medicine averaged about half a toilet trip and roughly 0.4 leaks fewer per day. Some people get a much larger benefit and others little at all. If the first medicine does not work well enough, another bladder medicine, a combination, or treatments such as botulinum toxin (Botox) injections into the bladder or nerve stimulation may be options. Mirabegron controls symptoms rather than curing the condition, so it is usually continued for as long as it helps, and it should not be stopped without talking to the prescriber. Blood pressure checks are part of ongoing follow-up. Children with a nerve-related bladder condition are followed by a specialist team, usually alongside a regular catheterization routine.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Myrbetriq (Mirabegron), what you've noticed, or ask the community a question.